European Journal of Cancer
Volume 46, Issue 18 , Pages 3233-3242 , December 2010

Expression of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinases 1 (TIMP-1) by colorectal cancer cells and adjacent stroma cells – Associations with histopathology and patients outcome

  • Søren Astrup Jensen

      Affiliations

    • Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Denmark
    • Corresponding Author InformationCorresponding author: Address: Department of Oncology, 5073 Rigshospitalet, Copenhagen University Hospital, 9 Blegdamsvej, Copenhagen DK-2100, Denmark. Tel./fax: +45 4589 4478.
    • ,
  • Ben Vainer

      Affiliations

    • Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Denmark
    • ,
  • Annette Bartels

      Affiliations

    • Section of Pathobiology, Department of Veterinary Disease Biology, Faculty of Life Sciences, University of Copenhagen, Denmark
    • ,
  • Nils Brünner

      Affiliations

    • Section of Pathobiology, Department of Veterinary Disease Biology, Faculty of Life Sciences, University of Copenhagen, Denmark
    • ,
  • Jens Benn Sørensen

      Affiliations

    • Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Denmark

Received 27 April 2010 ,Revised 26 July 2010 ,Accepted 29 July 2010.

References 

  1. Jensen SA, Vainer B, Kruhoffer M, Sorensen JB. Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression. BMC Cancer. 2009;9:25
  2. Roca F, Mauro LV, Morandi A, et al. Prognostic value of E-cadherin, beta-catenin, MMPs (7 and 9), and TIMPs (1 and 2) in patients with colorectal carcinoma. J Surg Oncol. 2006;93:151–160
  3. Curran S, Dundas SR, Buxton J, et al. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res. 2004;10:8229–8234
  4. Moran A, Iniesta P, Garcia-Aranda C, et al. Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer. Oncol Rep. 2005;13:115–120
  5. Takeuchi T, Hisanaga M, Nagao M, et al. The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer. Clin Cancer Res. 2004;10:5572–5579
  6. Baker EA, Leaper DJ. The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology. Eur J Cancer. 2003;39:981–988
  7. Waas ET, Lomme RM, DeGroot J, Wobbes T, Hendriks T. Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br J Cancer. 2002;86:1876–1883
  8. Ring P, Johansson K, Hoyhtya M, Rubin K, Lindmark G. Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer – a predictor of tumour stage. Br J Cancer. 1997;76:805–811
  9. Murashige M, Miyahara M, Shiraishi N, et al. Enhanced expression of tissue inhibitors of metalloproteinases in human colorectal tumors. Jpn J Clin Oncol. 1996;26:303–309
  10. Zeng ZS, Cohen AM, Zhang ZF, Stetler-Stevenson W, Guillem JG. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res. 1995;1:899–906
  11. Sutnar A, Pesta M, Liska V, et al. Clinical relevance of the expression of mRNA of MMP-7, MMP-9, TIMP-1, TIMP-2 and CEA tissue samples from colorectal liver metastases. Tumour Biol. 2007;28:247–252
  12. Guzinska-Ustymowicz K. MMP-9 and cathepsin B expression in tumor budding as an indicator of a more aggressive phenotype of colorectal cancer (CRC). Anticancer Res. 2006;26:1589–1594
  13. Lubbe WJ, Zhou ZY, Fu W, et al. Tumor epithelial cell matrix metalloproteinase 9 is a target for antimetastatic therapy in colorectal cancer. Clin Cancer Res. 2006;12:1876–1882
  14. Ogata Y, Matono K, Sasatomi T, et al. The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer. Cancer Chemother Pharmacol. 2006;57:577–583
  15. Saito K, Takeha S, Shiba K, et al. Clinicopathologic significance of urokinase receptor- and MMP-9-positive stromal cells in human colorectal cancer: functional multiplicity of matrix degradation on hematogenous metastasis. Int J Cancer. 2000;86:24–29
  16. Zeng ZS, Huang Y, Cohen AM, Guillem JG. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol. 1996;14:3133–3140
  17. Liabakk NB, Talbot I, Smith RA, Wilkinson K, Balkwill F. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res. 1996;56:190–196
  18. Tutton MG, George ML, Eccles SA, et al. Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients. Int J Cancer. 2003;107:541–550
  19. Inuzuka K, Ogata Y, Nagase H, Shirouzu K. Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma. J Surg Res. 2000;93:211–218
  20. Langers AM, Sier CF, Hawinkels LJ, et al. MMP-2 geno-phenotype is prognostic for colorectal cancer survival, whereas MMP-9 is not. Br J Cancer. 2008;98:1820–1823
  21. van der Jagt MF, Sweep FC, Waas ET, et al. Correlation of reversion-inducing cysteine-rich protein with kazal motifs (RECK) and extracellular matrix metalloproteinase inducer (EMMPRIN), with MMP-2, MMP-9, and survival in colorectal cancer. Cancer Lett. 2006;237:289–297
  22. Parsons SL, Watson SA, Collins HM, et al. Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy. Br J Cancer. 1998;78:1495–1502
  23. Islekel H, Oktay G, Terzi C, et al. Matrix metalloproteinase-9, -3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables. Cell Biochem Funct. 2007;25:433–441
  24. Moran A, Iniesta P, De Juan C, et al. Impairment of stromelysin-1 transcriptional activity by promoter mutations in high microsatellite instability colorectal tumors. Cancer Res. 2005;65:3811–3814
  25. Hilska M, Roberts PJ, Collan YU, et al. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer. 2007;121:714–723
  26. Holten-Andersen MN, Stephens RW, Nielsen HJ, et al. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res. 2000;6:4292–4299
  27. Oberg A, Hoyhtya M, Tavelin B, Stenling R, Lindmark G. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res. 2000;20:1085–1091
  28. Ishida H, Murata N, Hayashi Y, Tada M, Hashimoto D. Serum levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) in colorectal cancer patients. Surg Today. 2003;33:885–892
  29. Rhee JS, Diaz R, Korets L, Hodgson JG, Coussens LM. TIMP-1 alters susceptibility to carcinogenesis. Cancer Res. 2004;64:952–961
  30. Luparello C, Avanzato G, Carella C, Pucci-Minafra I. Tissue inhibitor of metalloprotease (TIMP)-1 and proliferative behaviour of clonal breast cancer cells. Breast Cancer Res Treat. 1999;54:235–244
  31. Li G, Fridman R, Kim HR. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res. 1999;59:6267–6275
  32. Liu H, Chen B, Lilly B. Fibroblasts potentiate blood vessel formation partially through secreted factor TIMP-1. Angiogenesis. 2008;11:223–234
  33. Zeng ZS, Guillem JG. Colocalisation of matrix metalloproteinase-9-mRNA and protein in human colorectal cancer stromal cells. Br J Cancer. 1996;74:1161–1167
  34. Zeng ZS, Guillem JG. Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 mRNA expression in human colorectal cancer and liver metastases. Br J Cancer. 1995;72:575–582
  35. Gallegos NC, Smales C, Savage FJ, Hembry RM, Boulos PB. The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancer. Surg Oncol. 1995;4:21–29
  36. Illemann M, Bird N, Majeed A, et al. MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases. Mol Cancer Res. 2006;4:293–302
  37. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol. 1996;149:273–282
  38. Karavasilis V, Malamou-Mitsi V, Briasoulis E, et al. Matrix metalloproteinases in carcinoma of unknown primary. Cancer. 2005;104:2282–2287
  39. Sorensen IV, Fenger C, Winther H, et al. Characterization of anti-TIMP-1 monoclonal antibodies for immunohistochemical localization in formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem. 2006;54:1075–1086
  40. Baker EA, Bergin FG, Leaper DJ. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Br J Surg. 2000;87:1215–1221
  41. Buhmeida A, Bendardaf R, Hilska M, et al. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in stage II colorectal carcinoma. J Gastrointest Cancer. 2009;40:91–97
  42. Unsal D, Akyurek N, Uner A, et al. Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy. Am J Clin Oncol. 2008;31:55–63
  43. Ohtani H. Stromal reaction in cancer tissue: pathophysiologic significance of the expression of matrix-degrading enzymes in relation to matrix turnover and immune/inflammatory reactions. Pathol Int. 1998;48:1–9
  44. Sorensen NM, Schrohl AS, Jensen V, et al. Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer. Scand J Gastroenterol. 2008;43:186–191

PII: S0959-8049(10)00756-2

doi: 10.1016/j.ejca.2010.07.046

European Journal of Cancer
Volume 46, Issue 18 , Pages 3233-3242 , December 2010

Article Tools

* Image Usage & Resolution